2014 September 15 | Posted by Quynh Doan
Easy ordering, fast delivery and enhanced support for EU customers
HAYWARD, CALIFORNIA, September 15, 2014:Advanced Cell Diagnostics Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, has announced the establishment of a European subsidiary which will start business in October 2014.
The move comes shortly after the company announced its probe library had grown to over 4000 probes andis indicative of the growing international demand for RNAscope® assays. The assays represent a major technological advance for in situ RNA detection, enabling robust single RNA molecule detection for the first time in formalin-fixed, paraffin-embedded (FFPE) tissue. Since their commercialisation three years ago, these assays have been adopted across the globe by major pharma biotech companies and leading research institutions for drug discovery, translational research, and the development of clinical and companion diagnostic tests.
The news also highlights ACD’s continued commitment to providing exceptional customer service to its global customers; “ACD is very excited about the rapid expansion of our customer base in Europe," said ACD's Chief Operating Officer Steve Chen. "Establishing a local subsidiary is a natural next step for us to extend our market presence and provide a faster and enhanced level of service to our customers here.”
The ACD European subsidiary has a warehousing and distribution centre located close to Milan, Italy, and sales, marketing and technical support staff in Germany and the UK. Such an arrangement offers significant benefits to European customers and eliminates troublesome and unpredictable import/export border issues. Product delivery becomes faster and more reliable with urgent orders of in-stock items able to be shipped next-day within Europe. In addition, customers will be able to place orders in Euros and technical and logistic support will be provided locally within the same time zone.
For further information, please visit www.acdbio.com.
About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell and tissue‐based diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the first automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single‐molecule sensitivity. RNAscope assays are currently used by hundreds of customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases. ACD’s industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop and commercialize proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope technology at www.acdbio.com.